Mathias Oelke, Ph.D.

Mathias Oelke, Ph.D., serves as the Chief Scientific Officer at NexImmune and is a co-founder of the company. He is recognized for pioneering the development of artificial Antigen Presenting Cell (aAPC) technology. With over two decades of research experience, Dr. Oelke has specialized in cellular immunology and T cell research, particularly focusing on cancer immunotherapy. His academic career includes a significant tenure as a faculty member at Johns Hopkins University from 2003 to 2014. Dr. Oelke earned his Ph.D. in Biology from the University of Freiburg, where he first developed an interest in the crucial role of antigen presenting cells in immunotherapy. He has been a co-inventor on more than 20 patents and patent applications that describe NexImmune’s proprietary aAPC technology, along with additional pending patent applications in related fields of cancer immunotherapy. His research has consistently aimed at developing methods for antigen-specific stimulation of T cells for therapeutic applications.